The French pharmaceutical group Sanofi announced this Friday, March 12, 2021, the launch of the first trials of its second vaccine project against Covid-19. It is a vaccine based on messenger RNA technology and the first intermediate results are expected in the third quarter of the year.
Launch of vaccine trials by Sanofi and Translate Bio
Sanofi and the American biotech Translate Bio have just announced the launch of their clinical trial on their candidate vaccine against Covid-19. In a press release issued this Friday, March 12, 2021, the French pharmaceutical group declared that it was about to start ” a 1/2 clinical trial devoted to their messenger RNA vaccine candidate against Covid-19 “.
As a reminder, phase 1 and 2 trials are the first to be carried out on humans and we must wait for phase 3 to determine the effectiveness of the treatment or vaccine in question. For the moment, Sanofi has planned to carry out its first tests on 415 people. It will then be necessary to wait until the third quarter to have intermediate results and to embark on the next phase.
A messenger RNA vaccine
This is the second vaccine developed by Sanofi in the fight against the coronavirus. The first vaccine, developed with the British GSK, was made on the basis of a recombinant protein. But clinical trials have been delayed and are only in phase 2. The French pharmaceutical group hopes to be able to launch it by the end of 2021.
As for the new vaccine candidate launched today by Sanofi and Translate Bio, it is based on the same technology as that used for the Moderna and Pfizer vaccines already authorized in the European Union. In addition, it is a messenger RNA vaccine that allows human cells to make S proteins and thus activate the immune response by making antibodies.
At the same time, the Sanofi group announced that it plans to help bottling anti-Covid vaccines developed by other groups such as Pfizer and Johnson & Johnson, whose vaccine has just been authorized in within the European Union.
